Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
J Thorac Oncol 2023 Jan 13;[EPub Ahead of Print], C Zhou, G Chen, Y Huang, J Zhou, L Lin, J Feng, Z Wang, Y Shu, J Shi, Y Hu, Q Wang, Y Cheng, F Wu, J Chen, X Lin, Y Wang, J Huang, J Cui, L Cao, Y Liu, Y Zhang, Y Pan, J Zhao, L Wang, J Chang, Q Chen, X Ren, W Zhang, Y Fan, Z He, J Fang, K Gu, X Dong, F Jin, H Gao, G An, C Ding, X Jiang, J Xiong, X Zhou, S Hu, P Lu, A Liu, S Guo, J Huang, C Zhu, J Zhao, B Gao, Y Chen, C Hu, J Zhang, H Zhang, H Zhao, Y Tai, X Ma, W Shi,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.